This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Astex Pharmaceuticals To Present At AACR-NCI-EORTC

DUBLIN, Calif., Oct. 14, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced four presentations of developmental and collaboration programs will be made at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 20 and 21, in Boston.

SGI-110 Abstract # A256  
Poster Presentation  Sunday, Oct. 20 12:30 - 7:30 p.m. EDT
Improved Antitumor Activity by Sequencing SGI-110 with CTLA-4 Blockade in a Syngenic Mouse Model
     
XIAP Abstract #A55  
Poster Presentation  Sunday, Oct. 20 12:30 - 7:30 p.m. EDT
Potent, dual cIAP1/XIAP antagonists induce apoptosis in a melanoma stem cell population
     
LEE011 Abstract #PR02  
Proffered Paper Session Sunday, Oct. 20 5:45 – 6 p.m. EDT
     
  Abstract #B264  
Novartis Poster Presentation Monday, Oct. 21 12:30 – 3 p.m. & 6:30 – 7:30 p.m. EDT
LEE011- An orally bioavailable, selective small molecule inhibitor of CDK4/6: Reactivating Rb in cancer
     
LEE011 Abstract #A276  
Novartis Poster Presentation Sunday, Oct. 20 12:30 - 3 p.m. & 6:30 – 7:30 p.m. EDT
Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas

Select posters will be made available for viewing on the Astex website http://astx.com/pipeline/publications/ .

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. Astex is developing a proprietary pipeline of novel therapies and is creating de-risked products for collaborations with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,039.49 +60.36 0.36%
S&P 500 1,992.37 +5.86 0.30%
NASDAQ 4,532.1040 +5.6220 0.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs